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Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in
developed countries, and its prevalence is projected to increase over the coming decades.
According to the World Health Organization, COPD will become the third leading cause of
death worldwide by 2020.
COPD has a chronic and progressive course, and is often aggravated by exacerbations, which
typically arise as a result of bronchial infection. Exacerbations are characterised by periods of
increasing acute symptoms, particularly cough, dyspnoea and production of sputum, which
worsen airflow obstruction, further impair quality of life and generally require a change in
regular medication. Exacerbations are the most common cause of medical visits, hospital
admissions and death in patients with COPD, and frequent exacerbations worsen health status
and may cause a permanent decline in lung function.
Chronic cough and sputum production are common in the general population, but signifi-
cantly more prevalent in patients with respiratory disorders; these symptoms have been sug-
gested as a risk factor for exacerbations of COPD. This article will review the consequences of
chronic cough and sputum production in patients with COPD and analyse whether these risk
factors may be useful for identifying a specific phenotype of patient that requires different
management to reduce the occurrence of exacerbations.
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Chronic obstructive pulmonary disease (COPD) is one of the
most prevalent diseases in developed countries and the
number of individuals affected has grown over recent
decades.1 A worldwide study of COPD prevalence from sites
in 12 different countries found an overall prevalence of
10.1%.2 However, most patients with COPD remain undiag-
nosed in the community. In Spain, where a similar COPD
prevalence of 10.2% among adults aged 40e80 years has
been reported, only 27% of sufferers had a previous diag-
nosis.3 Furthermore, the prevalence of COPD is projected
to increase over the coming decades as a result of
continued exposure to risk factors, coupled with the fact
that more people are now living to the age at which COPD
normally develops.4
In the USA, where more than 23 million people are
estimated to suffer from the disease, COPD accounted for
more than 119,000 deaths in 2000.5 The death rate is
increasing; death rates from COPD doubled in the USA
between 1970 and 2002, despite decreases in age-stand-
ardised death rates from stroke, heart disease and acci-
dents.6 In 2002, the World Health Organization Global
Burden of Disease Project estimated that COPD will be the
third leading cause of death worldwide by 2020.7
As well as high mortality, COPD carries considerable
morbidity due to its impact on lung function, which grad-
ually declines during the course of the disease. The chronic
and progressive course of COPD is often aggravated by
exacerbations e a sudden worsening of symptoms, partic-
ularly cough, dyspnoea and production of sputum, which
can become purulent. Most exacerbations are produced by
bronchial infections, and they are the most common cause
of medical visits, hospital admissions and death among
patients with chronic lung disease.8 Frequent exacerba-
tions worsen health status and may cause permanent
decline in lung function.9e12
Chronic cough and sputum production has been sug-
gested as a risk factor for COPD exacerbations and
progression of the disease.11,13e16 This article will consider
the evidence for this hypothesis and whether these risks
factors may be useful for identifying a specific phenotype
of patient that requires different management in order to
reduce the occurrence of exacerbations.Causes of chronic cough and sputum
production
The three main causes of chronic cough and sputum
production are smoking, bronchiectasis and chronic bron-
chitis, all of which may be related to each other in some
patients. The relationship between smoking and chronic
cough and sputum production is well established17 and the
number of pack-years has been shown to correlate with the
frequency of symptoms.18 Smoking triggers an inflammatory
reaction in the airways in susceptible individuals; such
a reaction results in increased secretion of mucus. In fact,
the numbers of visible mucous cells distal to the trachea
and the amount of mucin produced within the surface
epithelium are greatly increased during airway inflamma-
tion caused by smoking.19 A causative relationship between
second-hand smoke and chronic productive cough has also
been demonstrated.20
Analysis of computed tomography (CT) scans of the chest
demonstrated that at least 30% of patients with COPD have
bronchiectasis.21e23 The presence of bronchiectasis in
COPD is associated with more severe airflow obstruction,
the presence of bronchial colonisation by potentially
pathogenic microorganisms, and with previous hospital
admissions for exacerbations.24 In another study, lower
lobe bronchiectasis was reported most frequently in
patients with COPD, and was also associated with increased
frequency of bacterial colonisation of the lower airways,
more severe COPD exacerbations and increased inflamma-
tory markers in sputum.22 Chronic productive cough is the
most prominent symptom of bronchiectasis, occurring in
over 90% of patients.25
Chronic bronchitis is defined by the presence of cough
and sputum production for at least 3 months in each of two
consecutive years. However, chronic cough and sputum are
not synonymous with chronic bronchitis; such that patients
with these two symptoms do not always fulfill the criteria
for chronic bronchitis and moreover, the diagnosis of chronic
bronchitis requires other causes of chronic cough and
sputum production to be first ruled out. Chronic bronchitis
often coexists with emphysema and small airways disease,
and in some cases is the earliest manifestation of COPD in
smokers. In other individuals, however, chronic bronchitis
may be the only clinical manifestation of bronchial disease.
1120 M. MiravitllesThe reasons for differences in the evolution of pulmonary
disease in smokers are still unknown.
Prevalence of chronic cough and sputum
production
Chronic cough and sputum production are prevalent in the
overall population and are significantly increased in
subjects with respiratory disorders. Several population-
based health surveys of chronic respiratory symptoms have
shown a prevalence of chronic cough and/or sputum
production in the adult general population ranging from 4%
in never smokers to 50% in elderly smokers with COPD
(Table 1).3,13,17,26e34
In young individuals, aged 12e41 years, the lifetime
prevalence of chronic mucus hypersecretion has been
estimated in Finland as 8.6% in females and 6.9% in males.26
In the same country, a long-term epidemiological study of
middle-aged men showed that, by 75 years of age, the
cumulative incidence of chronic bronchitis in continuous
smokers was 42% (95% confidence interval [CI]: 38e47%),
26% (18e34%) in ex-smokers and 22% (16e28%) in those who
had never smoked.35 While it was previously believed that
15% of smokers developed COPD, Lundback et al. reported
that 50% of elderly smokers fulfill spirometric criteria for
COPD and, of these, 69% have a chronic productive cough.30
Thus, chronic cough and sputum production are common
symptoms in the general population, and their prevalence
increases with age and cumulative tobacco consumption.
Relationship between chronic cough and
sputum production and bronchial colonisation
and exacerbations in COPD
Colonisation is generally defined as the presence and
multiplication of microorganisms without necessarily
causing tissue invasion or damage. An exacerbation of COPD
has been defined by the American Thoracic Society and
European Respiratory Society as “an increase in respiratory
symptoms over baseline that usually requires a change in
therapy”.36 These events are often triggered by an infec-
tion and include increased breathlessness, cough and
sputum, fatigue and deteriorated health status, and
frequently require medical intervention.
If bronchial mucus becomes too thick, uncoupling may
occur within it so that the inner part, the sol phase, is
cleared by ciliary beating, while the outer part, the gel
phase to which bacteria adhere, remains stationary. In this
way, bacteria find favourable conditions for colonisation
and proliferation within the respiratory tract.37 It has been
shown that patients with chronic bronchitis without clinical
symptoms of exacerbation frequently have bacterial colo-
nisation of bronchial secretions,38 and some species, such
as Haemophilus influenzae, can also be found in different
lung tissues in these patients, in contrast to the sterile
lower airways in healthy adults.39 By using more sensitive
and specific sampling techniques, such as the protected
specimen brush, it has been reported that 25e50% of
patients with COPD carry potential pathogenic microor-
ganisms in the lower airways in the stable state,40 and thatsuch colonisation creates a cycle of epithelial cell damage,
impaired mucociliary clearance, mucus hypersecretion,
increased submucosal vascular leakage and inflammatory
cell infiltration.37
Beyond the vicious circle of colonisation and lung
damage, Patel et al. have shown that the presence of
bacterial colonisation in the stable state is also associated
with increased exacerbation frequency in patients with
moderate-to-severe COPD.41 Similarly, exacerbation has
been associated with the overgrowth and attainment of
a high bacterial load of colonising microorganisms.42 There
are three different theories to explain the increased
frequency of exacerbations in colonised patients. The first,
known as the “Fall and Rise” hypothesis, suggests that col-
onising bacteria may increase in number due to a variety of
stimuli (e.g. active smoking, lung function impairment, viral
coinfection, impairment of host defences) and produce
increasing bronchial and systemic inflammation with the
development of symptoms of exacerbation as a conse-
quence.43 Another hypothesis suggests that colonising
bacteria impair the local host defences and facilitate the
acquisition of a new and more pro-inflammatory bacterial
strain that causes the exacerbation.44 A less likely hypoth-
esis is that both colonisation and frequent exacerbations are
markers of severity of COPD and are influenced by the same
risk factors, but are not necessarily related to each other.
Existing evidence suggests that the first two hypotheses may
explain infective exacerbations in patients with COPD under
different circumstances.45
Epidemiological and observational studies have shown
an association between chronic cough and sputum or
chronic mucus hypersecretion and frequent exacerbations
and development of COPD.14e16,46e48 Examples are pre-
sented in Table 2.11,13,14,16,47,49,50 Other risk factors that
contribute to poor outcomes in COPD are summarised in
Table 3.11,16,47,49 The link between respiratory symptoms
and exacerbations is probably the increased frequency of
bacterial colonisation in patients with mucus hypersecre-
tion. This colonisation will facilitate the conditions for
exacerbations to develop.
Thus, mucus hypersecretion is an excellent milieu for
the proliferation of bacteria, and the carriage of bacteria in
the lower airways is associated with inflammation,51 and
increased frequency and severity of exacerbations.14Colonisation and exacerbations cause further
deterioration of COPD
There is accumulating evidence that exacerbations may have
an impact on the rate of decline in lung function in COPD. As
COPD patients with bacterial colonisation have more
frequent and purulent exacerbations,41 it is possible that
colonisation might indirectly accelerate the decline in lung
function through an increase in exacerbation frequency.
However, some studies have demonstrated that bacterial
colonisation by itself may harm the lungs. The sequence of
events may begin with an increase in bacterial load; this has
been demonstrated to be associated with increased release
of inflammatory mediators, such as interleukin (IL)-8, IL-6
and tumour necrosis factor (TNF)-alpha, both in sputum
and in bronchoalveolar lavage.41,44,52,53 Moreover, there is
Table 1 Overview of the prevalence of cough and sputum production in population-based studies.
Study Subjects Findings
Lange, et al. 198929 General population, Copenhagen;
random sample of 12,698 adult subjects
Prevalence of bronchial hypersecretion, 10.1%
Sobradillo, et al. 199933 General population, seven areas of Spain;
random sample of 4035 subjects aged
40e69 years
Prevalence of cough, 13.5%; expectoration,
10.7%; chronic bronchitis, 4.8%
Miravitlles, et al. 200631 General population, Spain; random sample of
6758 subjects aged > 40 years
Cough: 5% in never smokers, 11% in smokers
or ex-smokers;
16% in smokers of >20 pack-years
aged >55 years
Expectoration: 4% in never smokers,
11% in smokers and ex-smokers,
17% in smokers of >20 pack-years
aged >55 years
Miravitlles, et al. 20093 Population-based sample, Spain;
4274 adults aged 40e80 years
Chronic cough, 3.4%; chronic sputum
production, 11.7%
Cerveri, et al. 200117 General population, European Community;
random sample of 17,966 subjects aged
20e44 years in 16 countries
Median prevalence of chronic bronchitis,
2.6% (range 0.7e9.7% across countries)
von Hertzen, et al. 200034 7217 randomly selected subjects
(aged 30 years)
who participated in a comprehensive
health examination survey in Finland
Prevalence of chronic bronchitis and/or
emphysema: 22% in men, 7% in women.
Among those with COPD, chronic cough
and phlegm production was widely prevalent;
the lowest occurrence was in those with
pronounced obstructions (68% of men with
severe and 60% of women with moderate
obstruction)
Huchon, et al. 200227 General population, France; sample of
14,076 subjects aged  25 years using
self-administered questionnaire
Prevalence of chronic bronchitis, 4.1%;
chronic cough and/or
expectoration prevalence, 11.7%
Pallasaho, et al. 199932 Postal survey of random sample, Helsinki,
Finland; 8000 individuals aged 20e69 years
27% reported sputum production when
coughing
Janson, et al. 200128 Interview-led questionnaire; 18,277 subjects
aged 20e48 years from 16 countries
Prevalence of productive cough, 10.2%
Lundback, et al. 200330 Follow-up of 5892 individuals from the OLIN
Study cohort; 1500 randomly chosen responders
were invited to a structured interview and
a lung function test
Approximately 50% of elderly smokers
fulfilled BTS and GOLD criteria for COPD.
Of these, 60% had chronic productive cough
De Marco, et al. 200713 International cohort of 5002 subjects aged
20e44 years with normal lung function over
a median 8.9 years
At baseline, 9.2% reported chronic
cough/phlegm production
Harmsen, et al. 201026 Danish cohort of 29180 (in 1994) and 21130
(in 2004) twins aged 12e41 years
Cumulative prevalence of chronic
mucus secretion over 10 years of study,
10.7% in females and 8.7% in males
BTS: British Thoracic Society; COPD, chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease.
Cough and sputum production in patients with COPD 1121a close correlation between increased bacterial load in the
stable state and intensity of the inflammatory response of
bronchial epithelial cells.41,54 Some of these mediators are
chemoattractants for neutrophils, which increase in number
significantly in the presence of potentially pathogenic
microorganisms in the lower airways.53,55 As a consequence
of the attraction and activation of neutrophils, there is an
excess of myeloperoxidase and free elastase in the lungs of
COPD patients with bacterial colonisation.54,55 Not surpris-
ingly, the increase in concentration of sputum neutrophils is
correlated with greater deterioration in lung function in
patients with COPD.56,57 Results from an East London cohortstudy summarise this chain of events. In a group of 30
patients with severe COPD followed for 1 year, forced
expiratory volume in 1 s (FEV1) was found to decline in
relation to the increase in bacterial load and was also
greater in patients in whom there was a change in the col-
onising bacterial species. This study also showed that higher
concentrations of sputum IL-8 were associated with a faster
decline in FEV1 over the study period, supporting the studies
described above.58 A recent study found similar results in
a group of 40 patients with moderate-to-severe COPD who
were followed for 7e11 months (mean, 8 months). The
neutrophilic bronchial inflammatory response elicited by the
Table 2 Cough and sputum production as risk factors for poor outcomes in COPD.
Study Population Symptom(s) Association with outcome
Cough and/or sputum production as risk factors for exacerbations
Miravitlles,
et al. 200647
Observational, cross-sectional survey
of 1057 patients with stable COPD, Spain
Chronic mucus
hypersecretion
OR 1.53 (95% CI: 1.11e2.08;
p Z 0.009)
Burgel,
et al. 200914
Cross-sectional cohort of 433 patients
with COPD, France
Chronic cough and
sputum production
Estimated OR 4.15
(p < 0.0001)
Seemungal,
et al. 199811
Cohort study of 70 patients
with COPD, UK
Daily cough OR 3.30 (p Z 0.019)
Daily cough and sputum OR 3.80 (p Z 0.009)
Cough and/or sputum production as risk factors for failure of exacerbations
Niewoehner,
et al. 200716
Clinical trial of 1829 patients with
moderate-to-very severe COPD from
Veterans Affairs centres
Productive cough Relative hazard of failure:
1.32 (p Z 0.003)
Cough and/or sputum production as risk factors for COPD development
Lindberg,
et al. 200550
Patients with respiratory symptoms,
northern Sweden
Cougha OR 1.98 (95% CI: 1.10e3.58)b
Sputum productiona OR 1.77 (95% CI: 1.04e3.03)b
Chronic productive cougha OR 1.97 (95% CI: 1.19e3.26)b
Albers,
et al. 200849
General population, the Netherlands Mucus hypersecretion OR 1.88 (95% CI: 1.07e3.33)c
de Marco,
et al. 200713
International cohort of subjects
aged 20e44 yrs with normal lung
function followed for 10 yrs
Chronic cough with
sputum production
IRR 1.85 (95% CI: 1.17e2.93)
Chronic cough with
sputum production at
baseline and follow-up
IRR 2.88 (95% CI: 1.44e5.79)
OR: odds ratio; CI: confidence interval; IRR: incidence rate ratio.
a Definitions used in the study: cough: “Do you usually cough in the morning?” or “Do you usually cough at other times of the day?”,
sputum production: “Do you usually have phlegm when coughing?”, chronic productive cough: “Do you usually have phlegm when
coughing, or have phlegm which is difficult to bring up, most days for periods of at least three months, during at least the last two
years?”
b Adjusted for smoking and age.
c Adjusted for age, gender, number of pack-yrs at baseline and smoking behaviour.
1122 M. Miravitllespresence of potentially pathogenic microorganisms in the
lower airways was also associated with a significantly greater
decline in FEV1 during follow-up (odds ratio, 2.67; 95% CI
1.07, 6.62; p Z 0.03).59 These findings are from small
prospective studies and must be confirmed in larger cohorts
of patients with and without bronchial colonisation by
potentially pathogenic microorganisms.
Beyond the impact of bronchial colonisation by itself on
the rate of decline in lung function, the presence of
potentially pathogenic microorganisms in the airways of
patients with COPD is a risk factor for frequent and more
severe exacerbations, and, in turn, frequent exacerbations
will further accelerate the decline in FEV1.
60 Some studies
have described the impact of exacerbations on the rate of
decline in lung function. The primary evidence comes from
an analysis of data from the Lung Health Study that showed
an interactive effect of smoking and lower respiratory tract
illness in 5887 patients with mild COPD.9 Participants were
smokers aged 35e60 years with FEV1 55e90% predicted
(mild-to-moderate COPD). Over 5 years, lower respiratory
tract infection significantly increased the rate of FEV1
decline only in smokers and not in sustained quitters. In
smokers averaging one lower respiratory tract illness per
year over 5 years, there were additional declines in FEV1 of
7 ml/year (p Z 0.001); smokers with more than one lower
respiratory tract illness per year showed greater declines.Interestingly, chronic cough and sputum production were
associated with increased frequencies of lower respiratory
tract illness. In addition, early signs of chronic bronchitis,
even in the absence of detectable obstruction, have been
found to be associated with an increased risk for deterio-
ration in lung function and severe outcomes, including
mortality.61
In a study of patients with moderate-to-very-severe
COPD with a mean FEV1 of 38% predicted, the mean rate of
exacerbations was 2.92/year.12 The population cohort was
divided into two groups for comparison; patients with
a higher exacerbation rate than the mean were considered
frequent exacerbators and those with a lower rate were
considered infrequent exacerbators.12 The mean rate of
FEV1 decline in the total cohort was 36 ml/year, but was
greater among the frequent exacerbators compared with
the infrequent exacerbators (40.1 ml/year vs 32.1 ml/year,
respectively; p < 0.05). A similar effect of exacerbations
was seen in the Toward a Revolution in COPD Health
(TORCH) study, which investigated the effect of salme-
terol/fluticasone propionate and either component alone
compared with placebo on mortality, as well as the impact
on the rate of exacerbations, health-related quality of life
(HRQoL), and postbronchodilator FEV1. Patients who had
more frequent exacerbations, in the total population and in
the placebo group, showed a faster FEV1 decline than those
Table 3 Other risk factors for poor outcomes in COPD.
Study Population Risk factor Association with outcome
Other symptoms as risk factors for exacerbations
Miravitlles,
et al. 200647
Observational, cross-sectional
survey of 1057 patients with
stable COPD, Spain
SGRQ total score OR 1.04 (95% CI: 1.01e2.12; p < 0.0001)
Increased baseline
dyspnoea
OR 1.26 (95% CI: 1.00e1.60; p Z 0.041
Co-morbidity OR 1.47 (95% CI: 1.01e2.12; p Z 0.046)
GOLD stage IV OR 1.57 (95% CI: 1.05e2.34; p Z 0.049)
ICS treatment OR 2.14 (95% CI: 1.40e3.27; p Z 0.0004)
Other symptoms as risk factors for failure of exacerbations
Niewoehner,
et al. 200716
Clinical trial of 1829 patients
with moderate-to-very severe
COPD from Veterans Affairs centres
Theophylline at entry Relative hazard of failure:
1.26 (p Z 0.035)
Seemungal,
et al. 199811
Cohort study of 70 patients with COPD, UK Daily wheeze OR 4.20 (p Z 0.011)
Other symptoms as risk factors for COPD development
Albers,
et al. 200849
General population, The Netherlands Mild early respiratory
symptomsa
OR 2.08 (95% CI: 1.29e3.37)b
Below normal lung
function at baseline
OR 2.54 (95% CI: 1.25e5.19)b
CI: confidence interval; OR: odds ratio; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICS: inhaled corticosteroids; OR:
odds ratio; SGRQ: St George’s Respiratory Questionnaire.
a Combination of at least two out of three mild early signs (mild obstruction, reversibility, weather dependent, recurrent productive
cough).
b Adjusted for age, gender, number of pack-yrs at baseline and smoking behaviour.
Cough and sputum production in patients with COPD 1123without exacerbations; for patients with no exacerbations,
the mean rate of FEV1 decline in the active treatment
groups was between 26.9 and 30.7 ml compared with
55.6 ml in patients receiving placebo. In patients with one
or more exacerbations per year, the mean rate of FEV1
decline was between 52.6 and 58.8 ml in the active treat-
ment groups and 64.2 ml with placebo.62 These results show
that greater exacerbation frequency is associated with
greater decline in lung function, even in patients receiving
active treatment for COPD.
The hypothesis that repeated episodes of exacerbation
may potentially impair lung tissues and lead to an acceler-
ated rate of decline in pulmonary function is supported by a
number of observations.60,63 A study of 101 patients with
COPD followed for 2.5 years showed that exacerbationswere
associated with a transient decline in pulmonary function
and that these could take several weeks to return to base-
line.64 Increased concentrations of sputummyeloperoxidase
activity, indicating neutrophil influx, and inflammatory
markers, including IL-8 and leukotriene B4, have been
demonstrated in patients with recurrent exacerbations,
even in the stable phase of the disease.65 During exacerba-
tions, neutrophils are attracted into the airway lumen,66 and
in the absence of effective clearance may persist, creating
chronic bronchial inflammation. In a 15-year follow-up of
38 smokers and ex-smokers, FEV1 decline correlated
positively with the percentage of sputum neutrophils
(r Z 0.4, p < 0.01); subjects with >70% neutrophils in the
sputum showed a decline in FEV1 (27ml/year) that was twice
that observed in subjects with <70% neutrophils (12 ml/
year).67 Damage to lung tissue occurs as a result of exacer-
bations, as shown by a significant increase in lung elastindegradation products and free elastase in sputum during
exacerbations.65,68 In addition, desmosine, an elastin
degradation product and a potential marker of lung injury,69
was associated with a faster decline in FEV1 in patients with
COPD.70 As described earlier, a higher bacterial load in
respiratory secretions, such as that found during exacerba-
tions, is associated with increased inflammation and
decreased lung function in patients with stable chronic
bronchitis.54 Evidence suggests that bacterial load and
inflammation contribute to each other; this has been
demonstrated in a study that analysed bronchoalveolar
lavage in 39 patients with stable COPD (19 with frequent
exacerbations [3/year], and 20 with infrequent exacer-
bations) and in 18 healthy controls (10 smokers and 8 non-
smokers).71 Microorganisms with potential pathogenicity
above an established threshold were present in the bron-
choalveolar lavage of 68.4% of patients with frequent
exacerbations, 55% of those with infrequent exacerbations,
40% of smokers and 12.5% of non-smoker controls (pZ 0:05).
Levels of the inflammatory markers myeloperoxidase, IL-8
and TNF-a in bronchoalveolar lavage were found to be
significantly higher in the COPD patients compared with
controls (p Z 0.001).71 Finally, in support of all these
observations, the extent of anatomical emphysematous
changes on CT scans in the lungs of patients with COPD was
found to correlate with the number of previous exacerba-
tions.72 Thus, evidence is accumulating that frequent
exacerbations are associated with increased inflammation
and pathological changes that lead to an accelerated
decline in lung function.
In addition to the effects on lung function, exacerbations
of COPD also affect mortality rates. SolereCataluna et al.73
1124 M. Miravitllesreported that severe exacerbations of COPD requiring hos-
pitalisation were independently associated with all-cause
mortality. In a prospective cohort study of 304 men with
COPD who were followed for 5 years, acute exacerbations of
COPD were found to be independent indicators of a poor
prognosis. On multivariate analysis, the patients with the
greatest mortality risk were those with 3 acute COPD
exacerbations (hazard ratio 4.13, 95% CI: 1.80e9.41
compared with those with no acute exacerbations) (Fig. 1).
Evidence of the relationship between chronic
productive cough and sputum and the
evolution of COPD
Chronic cough and sputum production may affect disease
progression in COPD and COPD-associated mortality. In
early disease, several studies have confirmed an association
between mucus production and the rate of decline in
FEV1.
74e76 After adjusting for smoking, the presence of
a chronic productive cough correlated closely with lung
function decline in these studies. A study of patients with
a FEV1 of 80% predicted showed that those with higher
FEV1 had less goblet cell metaplasia than those with lower
FEV1, suggesting that the presence of mucin-producing cells
in the airways is related to increased airflow obstruction.77
It has also been suggested that mucus, by virtue of its
viscosity, could stick to airway walls, and therefore
contribute to luminal occlusion and lung function decline.78
The presence of chronic cough and sputum doubled the
risk of COPD in a cohort study of 5002 young adults (aged
20e44 years) with normal lung function followed for
a median of 8.9 years in the European Community Respi-
ratory Health Survey (ECRHS).13 Subjects who reported
chronic cough/phlegm both at baseline and follow-up had
a nearly threefold increased risk of developing COPD with
respect to asymptomatic subjects.
A follow-up study of the ECRHS showed that subjects
without asthma but with spirometrically defined mild/1.0
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Figure 1 KaplaneMeier survival curves by frequency of
exacerbations in patients with chronic obstructive pulmonary
disease (COPD): group A, patients with no acute exacerbations
of COPD; group B, patients with 1e2 acute exacerbations of
COPD requiring hospital management; group C, patients with
3 acute exacerbations of COPD. Reproduced with permission
from.73moderate COPD (n Z 5235) had a steeper lung function
decrease and a higher rate of hospitalisation for respiratory
causes than subjects without airflow obstruction. In
particular, symptomatic subjects (with or without airflow
obstruction) showed a higher and statistically significant
rate of respiratory care hospitalisation than asymptomatic
individuals with normal lung function. Smoking behaviour
and respiratory symptoms (chronic cough or phlegm and/or
dyspnoea) were found to be predictors of the longitudinal
outcomes in that study.79
Similarly, in a prospectively followed cohort of partici-
pants of the Framingham Offspring Study, the presence of
respiratory symptoms at baseline or a respiratory diagnosis
during follow-up identified a subpopulation of smokers who
were particularly susceptible to the deleterious effects of
smoking.80 Furthermore, in a population cohort study of 519
patients with Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage I COPD who were followed for 11 years,
those patients with respiratory symptoms (chronic cough,
sputum or shortness of breath while walking) had faster FEV1
decline, increased respiratory care utilisation and lower QoL
scores than patients who also had stage I COPD but without
symptoms. In addition, patients with GOLD stage I without
respiratory symptoms had no significant differences in these
outcomes compared with the reference group with normal
lung function.81 As COPD is often underdiagnosed in its early
stages, the evidence that chronic productive cough, which is
among the early symptoms of COPD, may be of predictive
diagnostic value (Table 2)11,13,14,16,47,49,50 is of paramount
importance. Individuals presenting with productive cough
should have spirometry performed for assessment of lung
function. If there is evidence of early airflow obstruction,
patients should be encouraged to stop smoking and should
be followed up to monitor disease progression and introduce
drug therapy when necessary.
In more severe disease, early investigations of the
association between chronic mucus hypersecretion and
COPD-related mortality failed to identify any predictive
value for sputum production.82 However, recent studies
have shown that sputum production can predict COPD-
related mortality, independent of ventilatory impairment
and smoking.61,83e85 Guerra et al. recently reported that
among adults aged <50 years, chronic bronchitis unac-
companied by airflow limitation may represent an early
marker of susceptibility to the effects of cigarette smoking
on systemic inflammation and long-term risk for COPD and
all-cause mortality.61 A long-term study of 101 patients
with severe or very severe COPD who had undergone lung
volume reduction surgery found that the only parameter
significantly related to survival was the severity of small
airway occlusion by exudates containing mucus.83 The
authors postulated that this could be due to excess mucus
production by goblet cells stimulated by neutrophil elastase
or oxygen-free radicals, or as a result of impaired mucus
clearance. The predictive value of sputum production for
mortality may be related to the infectious aetiology of
exacerbations; patients with COPD with chronic mucus
hypersecretion are more likely to succumb to pulmonary
infections than those without.85 A health survey of elderly
patients with respiratory symptoms indicated that 27.0%
(95% CI: 26.8e27.2) expectorated sputum on winter morn-
ings, and this subset of patients had an adjusted hazard
Primary
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2. Cough and
sputum production
5. Lung function decline
3. Bronchial colonisation
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6. Poor quality of life
7. Invalidity/death
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Figure 2 The downward spiral of chronic obstructive
pulmonary disease. (Adapted with permission from from la
Clinique du Souffle la Solane, Osse´ja, France, 1999).
Cough and sputum production in patients with COPD 1125ratio for all-cause mortality of 1.35 (95% CI: 1.21e1.50;
p < 0.001) and for respiratory-specific mortality of 2.01
(95% CI: 1.66e2.41; p < 0.001). Similar results were seen in
patients with wheezing, who had a prevalence of 14.3%
(95% CI: 14.1e14.5) and hazard ratios of 1.45 (95% CI:
1.31e1.61) for all-cause mortality and 2.86 (95% CI:
2.45e3.35; p < 0.001) for respiratory-specific mortality,
suggesting that the presence of respiratory symptoms is
a strong predictor of mortality.86
New studies have tried to identify phenotypes of COPD
according to different clinical, physiological and inflamma-
tory characteristics. In fact, chronic bronchitis reflects an
inflammatory sub-phenotype among patients with COPD, in
which there is a preferential distribution of inflammatory
cells towards the airway lumen. This may have implications
for current and future treatment strategies with anti-
inflammatory treatments in this phenotype.87 Using cluster
analysis of clinical, functional, inflammatory and radiolog-
ical data, different sub-phenotypes of patients with COPD
have been identified, and the presence of sputumproduction
was one of the key factors that helped to establish the
differences among them.88 It is possible that the existence of
these COPD sub-phenotypes may have therapeutic implica-
tions in the future.
Thus, although it may not be experienced by all patients,
chronic cough and sputum production are associated with
lung function decline and an increased rate of exacerbations
of COPD, and these symptoms have been suggested as
a predictive marker for respiratory-specific and all-cause
mortality.
The downward spiral in COPD
A spiral of decline in different aspects of COPD has been
suggestedas amodel of impairment in this disease.89 Smoking
or inspiring other irritants are recognised as the initiating
factors in COPD. The inflammation induced by these agents
causes mucus hypersecretion and chronic cough and sputum
production, which in turn is associated with frequent COPD
exacerbations, including severe episodes requiring hospital-
isation.14,16 Frequent exacerbations have been shown to
impair HRQoL in patients with COPD10 and are linked to an
accelerated decline in lung function.16,47 Thus, a ‘vicious
spiral’ of symptoms, exacerbations and lung function decline
occurs in patients with COPD (Fig. 2).Conclusions
Chronic cough and sputum production are highly prevalent
in patients with COPD and are predictive of disease
progression, exacerbations and hospitalisations. As such,
these symptoms constitute a marker of inflammation and
may identify patients at risk of clinical deterioration.
Appropriate and timely treatment in these patients may
help to reduce the frequency and impact of severe exac-
erbations. Furthermore, cough and sputum production may
be useful in the selection of patients at risk of exacerba-
tions for clinical trials of future therapies in COPD.
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